Drugs

Photo taken from Carl Ola Landgren/Twitter

Apr 26, 2024, 14:15

Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker

Carl Ola Landgren, Chief of the Myeloma Division and Translational Clinical Oncology Program at Sylvester Comprehensive Cancer Center, shared a post on X/Twitter:

“With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients’ access to new therapies will be much quicker.

Instead of waiting for 10-15 years, new drugs can be available in 3-5 years. Here is how it works.”

Source: Carl Ola Landgren/X

cancer Carl Ola Landgren MRD multiple myeloma Myeloma OncoDaily Oncology Sylvester Comprehensive Cancer Center Translational Clinical Oncology With Minimal Residual Disease

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage